President of the Executive Committee and Chief Science Officer
Lars Peter Brunse
Executive Vice President and Chief Production Officer
Executive Vice President and Chief Medical Officer
Executive Vice President and Chief People and Values Officer
Executive Vice President and Chief Commercial Officer
Secretary to the Executive Committee and Chief Legal Officer
Executive Vice President and Chief Financial Officer
Per joined Ferring Pharmaceuticals in 2015 and was appointed President from January 1st 2019. He also holds the role of Chief Science Officer, with responsibility for overseeing Ferring's Research, Development & Regulatory activities.
Prior to joining Ferring, Per held executive and senior leadership positions at Novo Nordisk and AstraZeneca in research, medical and clinical development roles.
For over 30 years, Per has been investigating and evolving microbiome science, holding faculty positions at some of the world’s leading institutions to advance research in this field. During his career, he has held the role of Associate Professor at the Karolinska Institute, Sweden and the Washington University School of Medicine, USA.
Per is a qualified medical doctor and also has a Ph.D. in Biochemistry and Clinical Chemistry.
Lars Peter Brunse
Lars Peter joined Ferring as Associate Director in 2000. Today he heads the Product Supply organisation with responsibility for the manufacturing and supply network of the Ferring Group.
He has led the expansion of Ferring’s manufacturing capability with the development of several state-of-the-art production sites, and extended the company’s product supply network from approximately 500 employees in 2000 to over 1,600 today.
Prior to joining Ferring, Lars Peter worked at Novo Nordisk in Manufacturing, Operational Excellence, and Quality Assurance Management. Lars Peter's professional career includes over 25 years in the pharmaceutical industry within Product Supply, Quality Control, Quality Assurance, Safety, Health & Environmental Affairs.
Lars Peter holds a Master degree in Pharmaceutical Sciences from University of Copenhagen.
Klaus joined Ferring in October 2017. He is responsible for Global Medical Affairs, Quality Assurance and Pharmacovigilance.
Prior to joining Ferring, Klaus held various leadership roles at Boehringer Ingelheim, including Vice President Global Medical Affairs, Chief Medical Officer, and, most recently, Managing Director UK & Ireland.
A Professor of Medicine, with a specialty in Internal Medicine, Klaus continues to teach medicine at Heidelberg University, Germany. He also spent four years carrying out research at the US National Institutes of Health (NIH) and has published more than 70 manuscripts in peer-reviewed journals including The Lancet and Diabetes.
Jean joined Ferring in November 2006 and is responsible for Compliance, Ethics, HR, Corporate Development, and Corporate Secretary on a global basis. Jean is also the Secretary to the Board of Directors of Ferring Holding S.A.
Prior to her arrival at Ferring, Jean was General Counsel at Elan Corporation, plc. She has a Bachelor of Science degree from Case Western Reserve University and a Juris Doctor degree from Ohio State University.
Aaron joined Ferring in 2002. Today he has operational responsibility for all commercial activities in Europe, Canada, Asia Pacific, Latin America and the Middle East & Africa. He is also responsible for Global Marketing and Business Development.
During his career Aaron helped accelerate Ferring’s growth in priority markets including Japan, China, S. Korea, Taiwan and Australia.
Prior to joining Ferring, Aaron worked for more than 17 years at Bristol-Myers-Squibb in a variety of sales, marketing and management positions in both the U.S. and Europe.
A native of Niagara Falls, NY, he holds a Master in Business Administration in Marketing from New York University and a Bachelor of Business Administration in Finance from the University of Michigan.
Curt joined Ferring in 2006 and is responsible for all Legal and Intellectual Property activities on a global basis. He has over 30 years of experience in the global pharmaceutical industry in various aspects of the business and in many different countries and cultures. He is also a writer of fiction and several of his short stories have been published.
Prior to joining Ferring, Curt worked at Eli Lilly and Company for over 16 years. He has a J.D. and an M.B.A. from Indiana University and B.A. from Purdue University.
Dominic joined Ferring in July 2017 as Chief Financial Officer. He has been a strategic advisor to executives and investors in biotech.
Dominic has 30 years’ finance and business experience in the life sciences industry. Previously, he worked for Takeda Pharmaceuticals as Global Financial Controller, and CFO of the international business following the acquisition of Nycomed. Prior to this Dominic worked for Hoffmann-La Roche, where he was CFO of the Pharma Division for nine years during a period of transformation and growth. He was engaged in numerous strategic initiatives and business transactions, as well as their operational implications, culminating in the privatisation of Genentech in the U.S. in 2009.
Dominic has an ACA from Institute of Chartered Accountants in England and Wales and a BSc in Chemistry from the University of Nottingham.